14 results
6-K
TAK
Takeda Pharmaceutical Co
2 Feb 24
Current report (foreign)
6:16am
functional worsening, time to relapse, change from pre-subcutaneous treatment baseline in Rasch-built Overall Disability Scale (R-ODS) centile score … as maintenance therapy to prevent the relapse of neuromuscular disability and impairment in adult patients. The approval is based on results from ADVANCE
6-K
TAK
Takeda Pharmaceutical Co
30 Oct 23
Current report (foreign)
6:02am
-subcutaneous treatment baseline in Rasch-built Overall Disability Scale (R-ODS) centile score and safety. Results showed a clinically significant reduction
6-K
TAK
Takeda Pharmaceutical Co
11 Sep 23
Current report (foreign)
6:50am
arthritis, physician global assessment of psoriatic arthritis, patient pain scale, disability history questionnaire and an acute phase reactant.9
About
6-K
TAK
Takeda Pharmaceutical Co
1 Aug 23
Current report (foreign)
6:10am
in Rasch-built Overall Disability Scale (R-ODS) centile score and safety. Results showed a clinically significant reduction in relapse rate with HYQVIA
6-K
EX-99.1
hnsrz12r3 jtww
29 Jun 21
Current report (foreign)
7:38am
6-K
EX-99.1
7pq9lz
6 Apr 21
Current report (foreign)
6:29am
6-K
EX-99.1
j3u06hxask 55h2hkv
17 Dec 20
Current report (foreign)
6:01am
6-K
EX-99.1
p6goyh3cjwygv3o5dls
8 Dec 20
Current report (foreign)
6:01am
S-8
EX-99.1
rtah3ti
25 Jun 20
Registration of securities for employees
6:21am
6-K
EX-99.1
upoojr0q7b
10 Jan 20
Better Health, Brighter Future 2019 SUSTAINABLE VALUE REPORT Takeda Pharmaceutical Company Limited
6:36am
- Prev
- 1
- Next